Liprolog Mix25

Insulin lispro, the active ingredient in Liprolog Mix25, is a rapid‑acting insulin analog presented as a subcutaneous injectable formulation for subcutaneous use. It is used to control blood glucose levels in adults and children with type 1 or type 2 diabetes mellitus.

GNH USA supplies Liprolog Mix25 as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable cold‑chain logistics for biologic products. Customers benefit from consistent product availability and regulatory support across multiple regions.

Liprolog Mix25, a rapid‑acting insulin analog, is employed to manage hyperglycemia in diabetes mellitus.

- Type 1 diabetes mellitus: provides rapid glucose control to match mealtime carbohydrate intake. - Type 2 diabetes mellitus: assists in achieving post‑prandial glucose targets when combined with basal insulin or oral agents. - Post‑prandial hyperglycemia: reduces spikes in blood glucose following meals.

The safety profile of insulin lispro includes both frequent and infrequent adverse reactions.

Common Side Effects: - Hypoglycemia: low blood glucose episodes, especially if meals are missed or dosing is excessive. - Injection site reactions: redness, swelling, or itching at the injection site. - Weight gain: modest increase in body weight with chronic use.

Serious or Rare Side Effects: - Severe hypoglycemia: neuroglycopenic symptoms requiring assistance. - Allergic reactions: urticaria, angioedema, or anaphylaxis. - Lipodystrophy: localized loss or accumulation of fat tissue at injection sites. - Hypokalemia: low serum potassium in rare cases.

When using Liprolog Mix25, clinicians should consider several precautionary measures to ensure safe therapy.

- Dose adjustment: tailor the dose based on individual glycemic response, renal function and carbohydrate intake. - Hypoglycemia risk: educate patients on recognizing and treating low blood glucose promptly. - Renal impairment: monitor kidney function as reduced clearance may increase insulin effect. - Pregnancy: use only if benefits outweigh potential risks; consult obstetric guidance. - Drug interactions: review concomitant medications that may potentiate or mask hypoglycemia. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Insulin lispro may interact with other medicines, altering its glucose‑lowering effect or masking hypoglycemia signs.

Major Interactions (Avoid): - Beta‑blockers: can mask hypoglycemia symptoms, requiring closer glucose monitoring. - Sulfonylureas: combined use may cause severe hypoglycemia. - Meglitinides: concurrent therapy increases risk of profound hypoglycemia.

Moderate Interactions (Monitor Closely): - Corticosteroids: may raise blood glucose, necessitating dose adjustments. - Thiazide diuretics: can affect glucose tolerance and insulin sensitivity.